NCT06607185 2026-04-22
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
City of Hope Medical Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
Emory University
AHS Cancer Control Alberta